Research in progress for novel protein kinase inhibitors: GEN

Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases, reports Genetic Engineering & Biotechnology News (GEN). Recent developments in the protein kinase inhibitor field include innovative paradigms for drug development, improved inhibitor profiling and selectivity strategies, and the expansion of disease targets (e.g., Alzheimer disease and traumatic brain injury), according to the June 1 issue of GEN (http://www.genengnews.com/gen-articles/kinase-inhibitor-obstacles-falling/3674/).

"Protein kinases underlie important cellular activities such as proliferation, metabolism, apoptosis, and differentiation, among others," says John Sterling, Editor in Chief of GEN. "They provide an excellent opportunity for a number of promising new drug products."

Researchers at ArQule, for example, are focusing on the inactive state of kinases. They carried out structural and functional studies on inhibitors of the c-Met receptor tyrosine kinase that is implicated in several cancers. The team subsequently co-crystallized their own small molecule inhibitor with inactive c-Met and reportedly discovered a conformation that is distinct from published kinase structures.

Scientists at Celgene are refining the company's in-house kinase selectivity strategy. They used Caliper Life Sciences' ProfilerPro kinase selectivity assay to find selectivity snapshots they were seeking.

Also covered in the GEN article is protein kinase inhibitor research taking place at Genentech, Merck Sharpe & Dohme, and the Harvard NeuroDiscovery Center.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Targeted degradation of Pin1 shows promise for pancreatic cancer treatment